Artigos de revistas sobre o tema "Inc Catapult"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 37 melhores artigos de revistas para estudos sobre o assunto "Inc Catapult".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Bishko, C. J. "St James's Catapult. The Life and Times of Diego Gelmírez of Santiago de Compostela. By R. A. Fletcher. Pp. xii + 341 inc. 2 maps. Oxford: Clarendon Press, 1984. £28." Journal of Ecclesiastical History 36, n.º 4 (outubro de 1985): 650–52. http://dx.doi.org/10.1017/s0022046900044067.
Texto completo da fonteWoyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett et al. "Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy". Blood 138, Supplement 1 (5 de novembro de 2021): 639. http://dx.doi.org/10.1182/blood-2021-153146.
Texto completo da fonteBannerji, Rajat, John N. Allan, Jon E. Arnason, Jennifer R. Brown, Ranjana H. Advani, Jeffrey A. Barnes, Stephen M. Ansell et al. "Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)". Blood 134, Supplement_1 (13 de novembro de 2019): 762. http://dx.doi.org/10.1182/blood-2019-122451.
Texto completo da fonteVartanov, Alexander R., Stacey M. Fernandes, Winnie I. Nguy, Danielle M. Brander, Svitlana Tyekucheva, Alexandra Savell, Allison P. Jacob et al. "High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)". Blood 134, Supplement_1 (13 de novembro de 2019): 4291. http://dx.doi.org/10.1182/blood-2019-124305.
Texto completo da fonteSpangler, Rhys, Timo Rantalainen, Paul Gastin e Daniel Wundersitz. "Inertial Sensors are a Valid Tool to Detect and Consistently Quantify Jumping". International Journal of Sports Medicine 39, n.º 10 (19 de julho de 2018): 802–8. http://dx.doi.org/10.1055/s-0044-100793.
Texto completo da fonteNaeem, Aishath S., Winnie I. Nguy, Svitlana Tyekucheva, Stacey M. Fernandes, Vanessa Rai, Kevin Ebata, Eliana B. Gomez, Barb J. Brandhuber, Stephen M. Rothenberg e Jennifer R. Brown. "LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL". Blood 134, Supplement_1 (13 de novembro de 2019): 478. http://dx.doi.org/10.1182/blood-2019-124362.
Texto completo da fonteMato, Anthony R., Kavita Sail, Maryam Sarraf Yazdy, Brian T. Hill, Mazyar Shadman, Beenish S. Manzoor, Hande H. Tuncer et al. "Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies". Blood 134, Supplement_1 (13 de novembro de 2019): 1756. http://dx.doi.org/10.1182/blood-2019-124600.
Texto completo da fonteShadman, Mazyar, Kavita Sail, Beenish S. Manzoor, Maryam Sarraf Yazdy, Brian T. Hill, Hande H. Tuncer, John N. Allan et al. "Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study". Blood 134, Supplement_1 (13 de novembro de 2019): 3048. http://dx.doi.org/10.1182/blood-2019-131401.
Texto completo da fonteLampson, Benjamin L., Svitlana Tyekucheva, Conner J. Shaughnessy, Annette S. Kim e Jennifer R. Brown. "Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients". Blood 134, Supplement_1 (13 de novembro de 2019): 1731. http://dx.doi.org/10.1182/blood-2019-127180.
Texto completo da fonteBrown, Jennifer R., Matthew S. Davids, Julie E. Chang, Shuo Ma, Juliana M. L. Biondo, Yong Mun, Madlaina Breuleux e William G. Wierda. "Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)". Blood 134, Supplement_1 (13 de novembro de 2019): 4320. http://dx.doi.org/10.1182/blood-2019-123665.
Texto completo da fonteLiu, Vivian M., Romain Guièze, Daniel Rosebrock, Alexis A. Jourdain, María Hernández-Sánchez, Aina Zurita Martinez, Elisa Ten Hacken et al. "MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers". Blood 134, Supplement_1 (13 de novembro de 2019): 1284. http://dx.doi.org/10.1182/blood-2019-131336.
Texto completo da fonteAllan, John N., Krish Patel, Anthony R. Mato, William G. Wierda, Javier Pinilla Ibarz, Michael Y. Choi, Susan M. O'Brien et al. "Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies". Blood 134, Supplement_1 (13 de novembro de 2019): 3041. http://dx.doi.org/10.1182/blood-2019-126286.
Texto completo da fonteMato, Anthony R., John M. Pagel, Catherine C. Coombs, Nirav N. Shah, Nicole Lamanna, Tahla Munir, Ewa Lech-Marańda et al. "Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study". Blood 138, Supplement 1 (5 de novembro de 2021): 391. http://dx.doi.org/10.1182/blood-2021-147599.
Texto completo da fonteFurman, Richard R., William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen et al. "Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study". Blood 134, Supplement_1 (13 de novembro de 2019): 3039. http://dx.doi.org/10.1182/blood-2019-128706.
Texto completo da fonteZheng, Dandan, Kavita Sail, Lindsey E. Roeker, Beenish S. Manzoor, Hande H. Tuncer, John N. Allan, Chaitra S. Ujjani et al. "Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)". Blood 136, Supplement 1 (5 de novembro de 2020): 19–22. http://dx.doi.org/10.1182/blood-2020-134676.
Texto completo da fonteChahal, Amandeep Kaur, Jolene Ziyuan Lim, Jing-Wen Pan e Pui Wah Kong. "Inter-Unit Consistency and Validity of 10-Hz GNSS Units in Straight-Line Sprint Running". Sensors 22, n.º 5 (28 de fevereiro de 2022): 1888. http://dx.doi.org/10.3390/s22051888.
Texto completo da fonteHillmen, Peter, Jennifer R. Brown, John C. Byrd, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Lugui Qiu et al. "Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)". Blood 134, Supplement_1 (13 de novembro de 2019): 4307. http://dx.doi.org/10.1182/blood-2019-124213.
Texto completo da fonteMato, Anthony R., Ian W. Flinn, John M. Pagel, Jennifer R. Brown, Chan Y. Cheah, Catherine C. Coombs, Manish R. Patel et al. "Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor". Blood 134, Supplement_1 (13 de novembro de 2019): 501. http://dx.doi.org/10.1182/blood-2019-127509.
Texto completo da fonteLancet, Jeffrey E., Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Stephen A. Strickland, Gary J. Schiller, Norbert Vey et al. "Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study". Blood 126, n.º 23 (3 de dezembro de 2015): 2560. http://dx.doi.org/10.1182/blood.v126.23.2560.2560.
Texto completo da fonteBachireddy, Pavan, Christina Ennis, Vinhkhang N. Nguyen, Nikolas Barkas, Sachet Shukla, Kendell Clement, Samuel Freeman et al. "Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)". Blood 134, Supplement_1 (13 de novembro de 2019): 516. http://dx.doi.org/10.1182/blood-2019-129520.
Texto completo da fonteTam, Constantine S., Ian W. Flinn, Alessandra Tedeschi, Emmanuelle Ferrant, Jennifer R. Brown, Tadeusz Robak, Paolo Ghia et al. "Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial". Blood 136, Supplement 1 (5 de novembro de 2020): 24–25. http://dx.doi.org/10.1182/blood-2020-134179.
Texto completo da fonteBrown, Jennifer R., Barbara F. Eichhorst, Paolo Ghia, Arnon P. Kater, Jianyong Li, Sudha Khurana, Mostafa Elhamy, Min Hui Wang e John F. Seymour. "A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation". Blood 134, Supplement_1 (13 de novembro de 2019): 4318. http://dx.doi.org/10.1182/blood-2019-123057.
Texto completo da fonteCrombie, Jennifer L., Svitlana Tyekucheva, Alexandra Savell, Karen Francoeur, Mark Choiniere, Josie Montegaard, Jacob D. Soumerai et al. "A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL". Blood 134, Supplement_1 (13 de novembro de 2019): 1763. http://dx.doi.org/10.1182/blood-2019-127343.
Texto completo da fonteMerryman, Reid W., Robert A. Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter, Kristin M. McHugh, Jennifer R. Brown et al. "Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma". Blood 136, Supplement 1 (5 de novembro de 2020): 22–23. http://dx.doi.org/10.1182/blood-2020-140965.
Texto completo da fonteBurke, Kathleen, Barrett Nuttall, Daniel L. Karl, Megan Callahan, Kerrin Mendler, Steven Criscione, Sergey Naumenko et al. "Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing". Blood 138, Supplement 1 (5 de novembro de 2021): 4361. http://dx.doi.org/10.1182/blood-2021-147113.
Texto completo da fonteDavids, Matthew S., Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai et al. "ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia". Blood 138, Supplement 1 (5 de novembro de 2021): 2634. http://dx.doi.org/10.1182/blood-2021-153033.
Texto completo da fonteLampson, Benjamin L., Svitlana Tyekucheva, Jennifer L. Crombie, Austin I. Kim, Reid W. Merryman, Jessica Lowney, Josie Montegaard et al. "Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)". Blood 134, Supplement_1 (13 de novembro de 2019): 32. http://dx.doi.org/10.1182/blood-2019-127506.
Texto completo da fonteDavids, Matthew S., Danielle M. Brander, Svitlana Tyekucheva, Chinheng Chen, James Kaminski, Josie Montegaard, Alvaro J. Alencar et al. "Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia". Blood 138, Supplement 1 (5 de novembro de 2021): 640. http://dx.doi.org/10.1182/blood-2021-146624.
Texto completo da fonteBall, William J. "Book Reviews : Beyond the Home Page Book Review Essay on Guides to Advanced Content Creation for the Web Introducing Microsoft FrontPage97. Kerry A. Lehto and W. Brett Polonsky. Redmond, WA: Microsoft Press, 1997. 384 pp., $24.99. Microsoft FrontPage97 Step by Step. Catapult Inc. Redmond, WA: Microsoft Press, 1997. 286 pp., $29.99. Web Scripting Secret Weapons. Scott Walker. Indianapolis, IN: Que Corp., 1997. 380 pp., $39.99. Special Edition Using JavaScript. Mark C. Reynolds. Indianapolis, IN: Que Corp., 1997. 831 pp., $49.99. VBScript by Example. Jerry Honeycutt. Indianapolis, IN: Que Corp., 1997. 355 pp., $34.99. Building VRML Worlds. Ed Tittle, Charlie Scott, Paul Wolfe, and Claire Sanders. Berkeley, CA: Osborne/McGraw Hill, 1997. 381 pp., $39.95". Social Science Computer Review 15, n.º 4 (dezembro de 1997): 446–50. http://dx.doi.org/10.1177/089443939701500411.
Texto completo da fonteSeymour, John F., John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard Furman et al. "Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)". Blood 138, Supplement 1 (5 de novembro de 2021): 3721. http://dx.doi.org/10.1182/blood-2021-146228.
Texto completo da fonteTedeschi, Alessandra, Emmanuelle Ferrant, Ian W. Flinn, Constantine S. Tam, Paolo Ghia, Tadeusz Robak, Jennifer R. Brown et al. "Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial". Blood 138, Supplement 1 (5 de novembro de 2021): 67. http://dx.doi.org/10.1182/blood-2021-144336.
Texto completo da fonteBrown, Jennifer R., Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, Henry Chan et al. "Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial". Blood 136, Supplement 1 (5 de novembro de 2020): 11–12. http://dx.doi.org/10.1182/blood-2020-134280.
Texto completo da fonteTam, Constantine S., Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti et al. "SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)". Blood 138, Supplement 1 (5 de novembro de 2021): 396. http://dx.doi.org/10.1182/blood-2021-148457.
Texto completo da fonteMakar, Piotr, Ana Filipa Silva, Rafael Oliveira, Marcin Janusiak, Przemysław Parus, Małgorzata Smoter e Filipe Manuel Clemente. "Assessing the agreement between a global navigation satellite system and an optical-tracking system for measuring total, high-speed running, and sprint distances in official soccer matches". Science Progress 106, n.º 3 (julho de 2023). http://dx.doi.org/10.1177/00368504231187501.
Texto completo da fonteWatts, Sophie P., Martyn J. Binnie, Paul SR Goods, Matthew M. Doyle, Jamie Hewlett e Peter Peeling. "Garmin wearable device offers reliable alternative for on-water stroke rate and velocity measurement in rowing". Proceedings of the Institution of Mechanical Engineers, Part P: Journal of Sports Engineering and Technology, 18 de maio de 2022, 175433712210993. http://dx.doi.org/10.1177/17543371221099364.
Texto completo da fonteKenawy, A., MY Khanji, M. Chirvasa, K. Fung, A. Sojoudi, JOSE M. Paiva, N. Samy, W. Farid, TS Khalil e SE Petersen. "Application of a machine learning contouring tool for the evaluation of left ventricular strain in clinical practice". European Heart Journal - Cardiovascular Imaging 22, Supplement_1 (1 de janeiro de 2021). http://dx.doi.org/10.1093/ehjci/jeaa356.259.
Texto completo da fonteSexton-Finck, Larissa. "Violence Reframed: Constructing Subjugated Individuals as Agents, Not Images, through Screen Narratives". M/C Journal 23, n.º 2 (13 de maio de 2020). http://dx.doi.org/10.5204/mcj.1623.
Texto completo da fonte